News Quantified

KPTI – karyopharm therapeutics inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1.3%

MISS

-5.8%

MISS

-20.0%

BEAT

-9.6%

BEAT

Cantor Fitzgerald

Cantor Fitzgerald

CANTOR FITZGERALD

Form 4 Karyopharm Therapeutics For: Feb 03 Filed by: Macomber Lori

Form 4 Karyopharm Therapeutics For: Jan 31 Filed by: Cheng Sohanya Roshan

Form 4 Karyopharm Therapeutics For: Jan 31 Filed by: Rangwala Reshma

Form 4 Karyopharm Therapeutics For: Jan 31 Filed by: Macomber Lori

Form 4 Karyopharm Therapeutics For: Jan 31 Filed by: Mano Michael

Top News Gainers

2/28 Form 3 Karyopharm Therapeutics For: Feb 26 Filed by: Paulson Richard A. 70.1%

9/16 Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million 10.7%

3/3 Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock 9.8%

5/15 Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award 8.6%

10/9 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%

1/8 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $21.00 price target on the stock. 7.2%

11/1 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 7.2%

4/20 Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 7.1%

11/4 Karyopharm Therapeutics Inc (KPTI) Q3 2019 Earnings Call Transcript [The Motley Fool] 6.9%

7/30 Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019 6.9%

Top News Decliners

3/13 Form S-8 Karyopharm Therapeutics -13.2%

3/12 Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer -13.1%

3/6 Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares -13.0%

7/5 Karyopharm Therapeutics Inc (NASDAQ: KPTI) had its price target raised by analysts at HC Wainwright from $29.00 to $32.00. They now have a "buy" rating on the stock. -11.5%

3/2 Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock -9.8%

1/17 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.5%

8/1 Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. -9.4%

3/5 Karyopharm Therapeutics: All Systems Go [Seeking Alpha] -9.0%

7/10 Karyopharm Therapeutics Inc (NASDAQ: KPTI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. -8.4%

3/17 Form 3 Karyopharm Therapeutics For: Mar 16 Filed by: DEMAREE JOHN -8.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day